financetom
Business
financetom
/
Business
/
HPCL Q4FY21 results: Seeing a 20% decline in demand in May, says management
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HPCL Q4FY21 results: Seeing a 20% decline in demand in May, says management
May 21, 2021 2:50 AM

State-run Hindustan Petroleum Corporation Ltd (HPCL) on Thursday reported its March quarter net profit soaring many folds to Rs 3,018 crore on the back of inventory gains and rise in refining margins. The company had a net profit of Rs 27 crore in January-March 2020.

Speaking with CNBC-TV18 on results, MK Surana, CMD of the company said that there is a 20 percent decline in demand in May as compared to April.

“In May, because of the localised lockdowns in various parts of the country, there was a dip in the demand. But I hope that with the positive trends emerging of the pandemic in some of the major states which suffered a lot and aggressive vaccination program, things should get back faster. There are some extension of lockdowns in some states, but we hope that by June things should be improving,” he said in an interview to CNBC-TV18.

On a normalised basis, however, Surana said that there is a dip of around 30 percent.

“If we compare to May 2020, it is more by almost 28 percent in petrol and 6 percent in diesel because last year May was a complete lockdown. On a normalised basis if we compare it, let us say May 2019, we have a dip of around 30 percent; May 2019 versus May 2021 on the motor spirit (MS) and high-speed diesel (HSD). Liquefied petroleum gas (LPG) is up around 15 percent,” he said.

He also said that last year the cracks and GRMs were quite low for MS and HSD, but it improved as the demand picked up in the US, Europe and Asia and the first wave of COVID receded.

Surana also said that according to projections Singapore's gross refining margins (GRMs) should improve hereon.

“Right now the Singapore GRMs as of May till date are in the range of USD 2.3/barrel which as compared to USD 0.53/barrel average of the last year, USD 1.78/barrel of Q4. The projections are that it should improve further here as the demand picks and the vaccination program gets underway in various parts of the country,” he said.

Surana also said that the company is not considering a buyback immediately and it has cash in books to the tune of Rs 2,500 crore.

Watch the video for more

(Edited by : Ajay Vaishnav)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sagimet Biosciences Q3 net loss narrows as costs drop
Sagimet Biosciences Q3 net loss narrows as costs drop
Nov 13, 2025
Overview * Sagimet reports Q3 net loss of $12.9 mln * R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024 * Cash and equivalents stand at $125.5 mln as of September 30, 2025 Outlook * Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026 * Company plans Phase 2...
Top Premarket Gainers
Top Premarket Gainers
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Mersana Therapeutics ( MRSN ) stock was up more than three-fold pre-bell Thursday after the company agreed to be acquired by Day One Biopharmaceuticals (DAWN) in a deal worth $285 million. Sealed Air ( SEE ) shares were 21% higher after The Wall Street Journal reported late Wednesday that the company is in...
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Nov 13, 2025
Overview * Arbutus Q3 revenue and net income missed analyst expectations * Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials * Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology Outlook * Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026 * 46% of Phase 2a patients discontinued treatment, showing potential...
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday it is expanding its RASP platform to include programs targeting central nervous system diseases associated with inflammation. The company said new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis showed improved grip strength, balance, and biomarkers of central nervous system function. The results...
Copyright 2023-2026 - www.financetom.com All Rights Reserved